We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Docetaxel Combination Produces 2-Year Survival Advantage in NSCLC Patients

Dec 1, 2001
Volume: 
15
Issue: 
12
  • Lung Cancer, Lung Cancer

According to a study presented at the 11th Annual
European Cancer Conference, patients with advanced non-small-cell lung cancer
(NSCLC) who received docetaxel (Taxotere) in combination with cisplatin (Platinol)
achieved better results than those in the control arm, who received vinorelbine
(Navelbine)/cisplatin. Most notably, the 2-year survival rate of the docetaxel/cisplatin
arm was significantly improved over that reported for the control arm: 21% of
the patients in the docetaxel/cisplatin arm were alive after 2 years, compared
to 14% of those treated with vinorelbine/cisplatin (P = .044). The
1-year survival rate in the docetaxel/cisplatin arm was 46%, compared to 41% in
the control arm (P = .044).

Three Treatment Arms

The study enrolled 1,220 patients with previously untreated advanced NSCLC.
Patients were randomized to one of three treatment arms. The first arm received
docetaxel followed by cisplatin every 3 weeks. The second group received
docetaxel followed by carboplatin every 3 weeks, and the third group
received a combination of vinorelbine and cisplatin every 4 weeks. Overall
exposure to chemotherapy was equivalent for all three groups.

In both docetaxel combination arms, quality of life and other clinical
benefit parameters such as body weight, performance status, and pain management
were improved compared to the control arm. In addition, the response rate was
significantly higher in the docetaxel/cisplatin arm than in the control arm (32%
vs 25%, P = .029). Time to progression was similar in both arms.

"The impressive impact on survival and quality of life demonstrated with
the docetaxel/cisplatin combination could profoundly change the treatment
standard of patients with NSCLC," said Frank V. Fossella, MD, medical
director, Thoracic Oncology Multidisciplinary Care Center at The University of
Texas M. D. Anderson Cancer Center in Houston.

Survival and Adverse Effects

The median survival of patients receiving the docetaxel/cisplatin regimen was
11.3 months vs 10.1 months for patients in the control arm (P = .044). The
overall survival of patients in the docetaxel/carboplatin arm was similar to
that of patients in the control arm. However, patients in the control arm
experienced significantly higher rates of nausea and vomiting, while diarrhea
was more common among patients in the docetaxel-based arm.

Pages

  • 1
  • 2
  • next ›
  • last »

Related Articles

  • Epacadostat/Durvalumab Combo Well Tolerated in Solid Tumor Trial
  • Antibiotics Reduced Efficacy of Checkpoint Inhibitors in RCC, NSCLC
  • Systemic Treatment Options for Brain Metastases from Non–Small-Cell Lung Cancer
  • New Option in NSCLC With IL-15 Agonist Plus Immune Checkpoint Inhibition
  • Durable Responses, Longer Survival Seen in NSCLC With Nivolumab at 5 Years

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.